The BCL-2 inhibitor received accelerated approval for patients with relapsed or refractory mantle cell lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sonrotoclax (Beqalzi) for the treatment of adult...
The bispecific antibody was approved for certain patients whose bile duct cancer harbors gene fusions that involve the neuregulin 1 gene. The U.S. Food and Drug Administration (FDA) approved zenocutuzumab-zbco (Bizengri) for the treatment...
Vepdegestrant is the first PROTAC approved for any cancer indication. The U.S. Food and Drug Administration (FDA) approved vepdegestrant (Veppanu) for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced...
Relacorilant was approved for previously treated ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA) has approved relacorilant (Lifyorli) in combination with nab-paclitaxel for the treatment of platinum-resistant epithelial ovarian,...
Simultaneously, previous accelerated approvals for nivolumab in relapsed/refractory advanced classical Hodgkin lymphoma were converted to full approvals. The U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) in combination with the chemotherapy regimen doxorubicin,...
The FDA has approved teclistamab with daratumumab hyaluronidase-fihj for certain patients with pretreated multiple myeloma. The U.S. Food and Drug Administration (FDA) approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj (Darzalex Faspro) for adult...
Zongertinib was granted accelerated approval as a first-line treatment for adults with advanced non-squamous non-small cell lung cancer with HER2-activating mutations. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zongertinib...
The FDA has converted the accelerated approval of encorafenib and cetuximab plus chemotherapy to full approval for first-line treatment of certain colorectal cancers. The U.S. Food and Drug Administration (FDA) has granted traditional approval...
The second-generation BTK inhibitor acalabrutinib was approved for use with venetoclax. The U.S. Food and Drug Administration (FDA) approved acalabrutinib (Calquence) in combination with venetoclax (Venclexta) for adults with chronic lymphocytic leukemia (CLL) or...
The FDA has approved the portable device Optune Pax for non-invasive at-home treatment of locally advanced pancreatic cancer. The U.S. Food and Drug Administration (FDA) approved Optune Pax, a portable, noninvasive device for the...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More